www.statnews.com Open in urlscan Pro
2606:4700::6812:1b65  Public Scan

Form analysis
2 forms found in the DOM

GET https://www.statnews.com/

<form class="header-search search-form" role="search" method="get" action="https://www.statnews.com/">
  <input type="search" class="search-form-field" placeholder="Search …" value="" name="s" aria-label="Search …">
  <button type="submit" class="header-btn header-btn-search">Search</button>
  <button class="header-btn header-btn-back">Cancel</button>
</form>

POST

<form id="coral-display-name-form" class="coral-display-name-form stat-form" method="post">
  <input type="text" id="enter-display-name-input" name="display" placeholder="Create a display name" value="">
  <p id="enter-display-name-error" style="display: none">There was an error saving your display name. Please check and try again.</p>
  <input type="submit" value="Continue">
</form>

Text Content

Skip to Main Content
 * 
 * 
 * 
 * Community

Try STAT+ TODAY

 * Contribute
 * Log In
 * Try STAT+ TODAY

My Account
 * My Account
 * Billing
 * Log In

Try STAT+ TODAY My Account
Search Cancel
 * TOPICS
   * Coronavirus
   * Health
   * Pharma
   * Biotech
   * Politics & Policy
   * Health Tech
   * In the Lab
   * Business
   * Artificial Intelligence
   * Vaccines
   * Health Disparities
   * Prescription Politics
 * OPINION
   * First Opinion
   * The Pharmalot View
   * Adam's Take
   * Matt's Take
   * Off the Charts
 * TEAM
   
   * Biotech & Pharma
     
     * Adam Feuerstein
     * Damian Garde
     * Matthew Herper
     * Meghana Keshavan
     * Kate Sheridan
     * Ed Silverman
     * Jonathan Wosen
   
   * Health Tech
     
     * Mario Aguilar
     * Katie Palmer
     * Mohana Ravindranath
     * Casey Ross
   
   * Business & Policy
     
     * Rachel Cohrs
     * Lev Facher
     * Nicholas Florko
     * Bob Herman
   
   * Health & Science
     
     * Eric Boodman
     * Helen Branswell
     * Angus Chen
     * Elizabeth Cooney
     * Isabella Cueto
     * Theresa Gaffney
     * Olivia Goldhill
     * Andrew Joseph
     * Megan Molteni
     * Usha Lee McFarling
     * Jennifer Adaeze Okwerekwu
     * Nicholas St. Fleur
   
   * Team
     
     * View All
 * EVENTS
   * Upcoming Industry Events
   * STAT Events
   * STAT Summits
   * 2022 STAT Breakthrough Science Summit
 * PODCASTS
   * Color Code
   * First Opinion Podcast
   * The Readout LOUD
 * NEWSLETTERS
 * RESOURCES
   * STAT Trials Pulse
   * Reports
   * E-books
 * VIDEO
 * 
 * STAT+
   
   * Exclusive analysis of biotech, pharma, and the life sciences
     
     Learn More
     * The Latest
     * My Account
   
   * Topics
     
     * Biotech
     * Pharma
     * Policy
     * Health Tech
     * Business
   
   * Columns
     
     * Adam's Take
     * Matt's Take
     * The Pharmalot View
   
   * Tools
     
     * CRISPR Trackr
     * Drug Pricing Policy Cheat Sheet
   
   * Events
     
     * STAT+ Conversations
     * All STAT Events
   
   * Team
     
     * Biotech and Pharma
     * Health Tech
     * Politics and Policy
     * Health and Science

Account

 * My Account
 * Billing
 * Subscribe
 * Log In
 * Help

More

 * Community
 * Contribute
 * Group Subscriptions

Follow Us

 * 
 * 
 * 
 * 
 * 

Trending:
Coronavirus
Biotech
Pharmalot
First Opinion

Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories

In-depth analysis of biotech, pharma, and the life sciences

 * AWARD-WINNING JOURNALISM
   
   from some of the nation's most trusted and well-connected reporters in the
   industry

 * WEEKLY LIVE VIDEO CHATS
   
   with STAT+ reporters and leading industry experts in our STAT+ Conversations
   series

 * EXCLUSIVE INDUSTRY EVENTS
   
   hosted by STAT+, plus early-bird access and discounts to industry events
   around the country

 * DAILY STAT+ NEWSLETTERS
   
   get delivered to your inbox to brief you on the most important industry news
   of the day

 * PREMIUM DATA TOOLS
   
   like our CRISPR Trackr and Drug Pricing Policy Tracker


EXCLUSIVE COVERAGE AND ANALYSIS OF BIOTECH, PHARMA, AND THE LIFE SCIENCES

Try STAT+ 30 days FREE Learn More

In-depth analysis of biotech, pharma, and the life sciences

 * AWARD-WINNING JOURNALISM
   
   from some of the nation's most trusted and well-connected reporters in the
   industry

 * WEEKLY LIVE VIDEO CHATS
   
   with STAT+ reporters and leading industry experts in our STAT+ Conversations
   series

 * EXCLUSIVE INDUSTRY EVENTS
   
   hosted by STAT+, plus early-bird access and discounts to industry events
   around the country

 * DAILY STAT+ NEWSLETTERS
   
   get delivered to your inbox to brief you on the most important industry news
   of the day

 * PREMIUM DATA TOOLS
   
   like our CRISPR Trackr and Drug Pricing Policy Tracker


EXCLUSIVE COVERAGE AND ANALYSIS OF BIOTECH, PHARMA, AND THE LIFE SCIENCES

Try STAT+ 30 days FREE Learn More
Business


THE BIGGEST PBMS ARE HANDLING MORE AND MORE OF THE COUNTRY’S DRUG PRICE
NEGOTIATIONS

 * 

By Bob Herman March 22, 2022

Reprints
 * + Comments
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 

Adobe
 * 0 Comments
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 

Alex Schmelzer didn’t think he’d be the most-hated person in drug pricing
negotiations, but he was.

Schmelzer founded a consulting firm in 2016 to help companies battle their
pharmacy benefit managers, the behemoth intermediaries that negotiate drug
prices, process claims, and create networks of pharmacies. Schmelzer and his
colleagues pored through data and discovered many employers were paying too much
for their workers’ drugs. 

Unlock this article — plus daily market-moving biopharma analysis — by
subscribing to STAT+. First 30 days free.

GET STARTED
Log In
 * 0 Comments
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 


ABOUT THE AUTHOR REPRINTS


BOB HERMAN

Business of Health Care Reporter

Bob Herman is a business of health care reporter at STAT. He covers hospitals,
health insurance, and other corners of the industry — with a goal of explaining
and shining light on the massive amount of money flowing through the system.


bob.herman@statnews.com

@bobjherman


TAGS

drug pricing

insurance

pharmacy benefit manager

STAT+


Add a Comment


CREATE A DISPLAY NAME TO COMMENT

This name will appear with your comment

There was an error saving your display name. Please check and try again.




EXCLUSIVE BIOPHARMA, HEALTH POLICY, AND LIFE SCIENCE ANALYSIS. START YOUR 30-DAY
FREE TRIAL TODAY.

TRY STAT+


CATCH UP ON THE LATEST MUST-READ COVERAGE AND ANALYSIS

Read Now

advertisement



 * 
   Teva and Allergan reach $107 million deal with Rhode Island over opioid
   crisis
 * 
   When should drugmakers go all in and cut off essential medicines to Russia?
 * 
   Illumina sues Guardant Health, saying former employees stole trade secrets to
   launch liquid biopsy firm

Learn more about STAT+

advertisement



Trending
What makes a biotech a biotech?
What makes a biotech a biotech?

After a dry spell for cancer immunotherapy, a new…
After a dry spell for cancer immunotherapy, a new target offers a beacon of hope

Doctors often turn to Google Translate to talk to…
Doctors often turn to Google Translate to talk to patients. They want a better
option
Recommended
An ALS therapy sets up a crucial test of…
An ALS therapy sets up a crucial test of the FDA’s independence

‘Harmful and wasteful’: Many pediatric clinical trials end early…
‘Harmful and wasteful’: Many pediatric clinical trials end early or don’t report
results

Teva and Allergan reach $107 million deal with Rhode…
Teva and Allergan reach $107 million deal with Rhode Island over opioid crisis


RECOMMENDED STORIES

Business


PATIENTS ARE FLOCKING BACK TO HOSPITALS, BUT VOLUMES ARE AT THE MERCY OF COVID
SURGES, NEW DOCUMENTS SHOW

By Bob Herman

Health


‘IT’S NOT MEDICAL’: OREGON WRESTLES WITH HOW TO OFFER PSYCHEDELICS OUTSIDE THE
HEALTH CARE SYSTEM

By Olivia Goldhill

advertisement


Exclusive


NEW DETAILS EMERGE ABOUT A U.S. SCIENTIST’S OBSCURED ROLE IN THE ‘CRISPR BABIES’
SCANDAL

By Megan Molteni

Pharmalot


CUTTING-EDGE GENE THERAPIES COULD BE COMING FOR SICKLE CELL. WILL MEDICAID
PATIENTS BE ABLE TO ACCESS THEM?

By Ed Silverman

A STAT Investigation


AI GONE ASTRAY: HOW SUBTLE SHIFTS IN PATIENT DATA SEND POPULAR ALGORITHMS
REELING, UNDERMINING PATIENT SAFETY

By Casey Ross

Reporting from the frontiers of health and medicine

Trending:
 * Coronavirus
 * Biotech
 * Pharmalot
 * First Opinion
 * Health
 * Health Tech

Back to top


COMPANY

 * About STAT
 * Awards
 * Contact Us
 * Careers & Internships
 * Contribute
 * Diversity & Inclusion
 * Licensing Stories
 * Our Team


ACCOUNT

 * About STAT+
 * FAQs
 * Log In
 * Subscribe


APP & OTHER PRODUCTS

 * STAT App
 * Newsletters
 * Podcasts
 * STAT Madness
 * STAT Reports
 * STAT Trials Pulse
 * STAT Wunderkinds


GROUP SUBSCRIPTIONS

 * Contact Us
 * Request A Quote


ADVERTISING

 * Advertise With Us
 * Download Media Kit


EVENTS

 * Upcoming Industry Events
 * STAT Events
 * STAT Summits
 * Sponsor An Event

 * Privacy
 * Comment Policy
 * Terms
 * Do Not Sell my Data
 * ©2022 STAT

 * 
 * 
 * 
 * 
 * 




Please review our cookie policy

We use first- and third-party cookies to customize your experience and display
advertising. By continuing to use the site, you agree to our use of cookies. If
you want to know more or opt out in whole or in part, please see our Privacy
Notice and our Cookie FAQ.

Accept No thanks